[{"orgOrder":0,"company":"CaroGen","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 Vaccine Recombinant","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CaroGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CaroGen \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"CaroGen \/ Yale University"}]

Find Clinical Drug Pipeline Developments & Deals by CaroGen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          DIA 2025
                          Not Confirmed
                          DIA 2025
                          Not Confirmed

                          Details : CaroGen team up with Yale University School of Medicine to develop AVIDIO/SARS-CoV-2 recombinant vaccine for COVID-19.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          October 03, 2020

                          Lead Product(s) : SARS-CoV-2 Vaccine Recombinant

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Yale University

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank